Peripheral hypothyroidism and TAFRO syndrome: Particularity of management
Department of Endocrinology Diabetology and Metabolic Diseases, PCIM Laboratory, FMPM, Cadi Ayyad University, CHU Mohamed VI Marrakech.
Case Study
World Journal of Advanced Research and Reviews, 2023, 17(02), 742–744
Article DOI: 10.30574/wjarr.2023.17.2.0300
Publication history:
Received on 09 January 2023; revised on 20 February 2023; accepted on 22 February 2023
Abstract:
TAFRO syndrome is defined by the presence of thrombocytopenia, hydrops, fever, fibrosis, renal dysfunction, and organomegaly and can be seen with idiopathic multicentric Castleman disease (iMCD) or as an isolated process without iMCD. The pathophysiology of TAFRO is not well understood, but it is thought to be related to hypercytokinemia. Subclinical hypothyroidism may be a potential factor in the pathogenesis and symptomatology of TAFRO syndrome with elevated vascular endothelial growth factor (VEGF).There are no clear guidelines for the treatment of TAFRO in the absence of a definitive diagnosis of iMCD, resulting in suboptimal management and high morbidity. We report a case of hypothyroidism revealed by TAFRO syndrome.
Keywords:
Hypothyroidism; TAFRO syndrome; VEGF; Management
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0